Actively Recruiting
Evaluating the Safety and Effects of Lacripep 4 cM Eye Drops Compared to Placebo in People with Stage 1 Neurotrophic Keratitis
Led by TearSolutions, Inc. · Updated on 2026-09-25
54
Participants Needed
6
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and effects of Lacripep 4 cM Ophthalmic Solution on the eye surface, vision, corneal sensitivity, and quality of life in people with Stage 1 neurotrophic keratitis NK. The study is a phase 2, randomized, vehicle-controlled trial comparing Lacripep to a placebo solution in subjects with this condition. Participants will first go through a 2-week run-in period using the placebo vehicle eye solution openly. Then, they will be randomly assigned to use either Lacripep or the vehicle solution three times daily in both eyes for 8 weeks. Clinic visits are scheduled at Week 2, Week 4, and Week 8 for assessments. After Week 8, all subjects will receive open-label Lacripep treatment for 4 additional weeks while continuing the same dosing schedule. Throughout the study, participants will have their eye images reviewed centrally to ensure unbiased grading. Researchers will monitor safety, eye surface health, visual function, corneal sensitivity, and quality of life. The total study duration for treatment is 12 weeks, with regular clinic visits and evaluations to assess the effects of the study eye drops.
CONDITIONS
Brief Title
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Research Team
M
Marc Odrich, MD
M
Michelle Carpenter
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here